Companies › RayzeBio
3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RYZ101 Actinium-225 labeled somatostatin receptor agonist (SSTR-targeting radiopharmaceutical) | SSTR2 | Phase 3 | GEP-NET; SCLC,Extensive Stage; Metastatic Breast Cancer | Dec 2026 |
| RYZ401 Ac-225-based targeted alpha therapy for somatostatin receptor expression | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 1 | GEP-NET | Feb 2027 |
| RYZ801 GPC3-targeted alpha-emitting radiotherapeutic (Ac-225 conjugate) | GPC3 | Phase 1 | Hepatocellular Carcinoma (HCC) | Jun 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05477576 | RYZ101 | Phase 3 | GEP-NET | Oncology | Dec 2026 |
| NCT07165132 | RYZ401 | Phase 1 | GEP-NET | Oncology | Feb 2027 |
| NCT05595460 | RYZ101 | Phase 1 | SCLC,Extensive Stage | Oncology | Jul 2027 |
| NCT06590857 | RYZ101 | Phase 1 | Metastatic Breast Cancer | Oncology | Oct 2028 |
| NCT06726161 | RYZ801 | Phase 1 | Hepatocellular Carcinoma (HCC) | Oncology | Jun 2030 |
PharmaMar Day One Biopharmaceuticals ArriVent BioPharma Nuvalent Jiangsu Alphamab Biopharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.